-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23

Benzinga·06/25/2026 13:34:34
Listen to the news
Chardan Capital analyst Andreas Argyrides maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $21 to $23.